Neuvoir Pharmaceuticals has been awarded over £99,000 in Smart:Scotland funding from Scottish Enterprise to support the development of Pharmoris®, its AI-enabled medicines intelligence and deployment programme.
The funding will support a nine-month feasibility study exploring how artificial intelligence can help the NHS identify, assess and deploy high-value generic medicine opportunities more efficiently.
Neuvoir supports governed pharmaceutical intelligence infrastructure, turning medicines data into trusted decisions and measurable value across healthcare systems. Pharmoris applies that approach to a persistent challenge in health systems, namely actionable medicines data, cost pressures, supply risks and implementation decisions. These often sit across different teams and organisations, making opportunities difficult to prioritise and implement. The Smart:Scotland project will test whether Pharmoris can help close that gap by developing:
· AI-supported prioritisation models for high-impact generic medicine opportunities
· Regulatory and evidence-template workflows, including MHRA-compliant dossier structures
· NHS deployment simulations to assess potential cost, access, supply-resilience and implementation benefits.
The project is designed to assess technical feasibility and commercial potential, with the longer-term aim of helping NHS organisations make faster, better-evidenced decisions on generic medicines while keeping clinical, regulatory, financial and governance judgement within human teams.
The award strengthens Neuvoir’s position as a Glasgow-based life-sciences software company working at the intersection of medicines access, generics strategy, regulatory intelligence and AI-enabled health-system infrastructure.
Pharmoris supports Neuvoir’s wider ambition to build intellectual property and high-value technical capability in Scotland, while contributing to more resilient and cost-effective medicines deployment across health systems. The feasibility study will run through 2026 and will inform the next stage of Pharmoris development, including future discussions with NHS and health-system partners.
The Smart award follows the Innovate UK funding awarded Neuvoir as the company founded in Glasgow in 2025 continues to scale.
